Bayer, NextRNA Therapeutics to Collaborate on New Class of Tumor Treatment
By Pierre Bertrand
Bayer and U.S. biotechnology company NextRNA Therapeutics agreed to collaborate on the development of small molecules to be used in the treatment of tumors.
NextRNA, based in Boston, is to get up to $547 million for the development of two small-molecule programs, the companies said.
They aim for the molecules to serve as a new class of therapeutic agents disrupting a key driver in the growth of tumors, the companies said.
Bayer and NextRNA will work together on a first program already in early preclinical development. In the second, Bayer will have the option to select one target for joint development.
Included in the agreement's funds are upfront and near-term milestone payments, development and commercial milestone payments, research funding as well as tiered royalties on net sales, according to the companies.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
August 28, 2024 07:14 ET (11:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now